MOSCOW, April 19. /TASS/. The efficacy of the Sputnik V vaccine has amounted to 97.6%, as follows from the analysis of data on 3.8 mln inoculated Russians, the Russian Direct Investment Fund (RDIF) reported.
"The Gamaleya National Research Center and the RDIF announce the efficacy of the Sputnik V vaccine at the level of 97.6%, as follows from the analysis of data on coronavirus incidence among Russians inoculated with both components of the preparation," the statement said.
According to data on vaccination of 3.8 mln Russians who received both components during the period from December 5, 2020 through March 31, 2021, the incidence beginning on Day 35 after the first injection amounted only to 0.027%.
"At the same time, the incidence among the unvaccinated adult population was 1.1% for a comparable period starting from the 35th day after the launch of mass-scale vaccination in Russia," the RDIF said, adding that the data on and calculations of the vaccine’s efficacy will be published in a peer-reviewed medical journal in May.
Russia was the world’s first to register an anti-coronavirus vaccine in August 2020. The vaccine, developed by the Gamaleya National Research Center for Epidemiology and Microbiology of the Russian Health Ministry, was given the name Sputnik V. It is a vector vaccine based on the human adenovirus.
In early February 2020, The Lancet, a world-acclaimed medical journal, published the results of the third phase of Sputnik V clinical tests. The vaccine has proved to be among the world’s safest and most efficient. Thus, its efficacy was estimated at 91.6% and 91.8% among volunteers older than 60.
The vaccine has been registered in around 60 world nations, with an overall population of more than 1.5 billion. It is the world’s second most popular vaccine.